Carbimazole-Induced Acute Cholestatic Hepatitis

Ozenne, G.; Manchon, N. D.; Doucet, J; Hémet, J; Schrub, J. C.; Bercoff, É.

doi:10.1097/00004836-198902000-00025

Cited by 15 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[910] Carbimazole and methimazole, on the other hand have been typically associated with cholestatic jaundice (mainly hyperbilirubinemia) without evidence of hepatic necrosis on liver biopsy. [2611] Most patients recover on drug discontinuation. Nevertheless, there are occasional reports of severe and fatal cases with methimazole-induced liver disease.…”

Section: Discussionmentioning

confidence: 99%

“…Hepatic toxicity is a rare, but serious side effect with both methimazole (and its pro-drug, carbimazole) and propylthiouracil (PTU). [123] Fatal cases have been documented with both drugs. [4] The hepatic histopathological findings with PTU are toxic hepatitis with necrosis,[5] whereas, they resemble cholestatic hepatitis with methimazole (and carbimazole).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Carbimazole-induced cholestatic hepatitis in Graves′ disease

Kota

Meher

Kota

et al. 2013

Indian J Endocr Metab

View full text Add to dashboard Cite

Antithyroid medications are one of the treatment options for Graves’ disease. Carbimazole is widely used as the drug of choice, except in pregnancy, where propythiouracil is preferred by many. It is generally well-tolerated. Its side-effects include allergy, upper gastrointestinal upset, a rare occurrence of granulocytosis, and others. Hepatitis is another rare, but serious side-effect. We report a healthy 30-year-old male patient with Graves’ disease, who developed cholestatic jaundice after Carbimazole therapy for four months. He made a full recovery after the drug was discontinued. An idiosyncratic mechanism seemed likely.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Carbimazole-induced cholestatic hepatitis in Graves′ disease

Kota

Meher

Kota

et al. 2013

Indian J Endocr Metab

View full text Add to dashboard Cite

show abstract

“…In a small number of cases of presumed methimazole-induced liver dysfunction, an elevation of bilirubin was the major abnormality and in most of these case reports, mild elevations in liver enzymes and bilirubin occurred within 2 weeks of initiation of methimazole therapy and in liver biopsy specimens preserved hepatocellular architecture along with intracanalicular cholestasis and mild periportal inflammation was observed. Complete, slow recovery is the rule after drug discontinuation [8][9][10][11][12][13][14][15][16][17].…”

Section: Discussionmentioning

confidence: 99%

“…At the time of presentation, laboratory baseline values were compatible with hyperthyroidism [FT3 = 17.3 pg/ml (nv: 2.3-5.3), FT4 = 47.8 pmol/l (nv: [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25], and TSH = 0.047 mu/l (nv: 0.3-4)], followed with normal liver values. The patient was advised to stop the OCP's medication and start treatment with antithyroid drugs and beta-blockers on the following regimen: methimazole 20 mg S:1 9 3 and propranolol 40 mg, S:1/2 9 3.…”

Section: Introductionmentioning

confidence: 99%

Liver failure due to antithyroid drugs: report of a case and literature review

Livadas

Xyrafis

Economou

et al. 2010

Endocr

View full text Add to dashboard Cite

Hyperthyroidism is a common endocrine disorder affecting 2% of females and 0.5% of males worldwide and antithyroid drugs constitute the first line of treatment in the majority of cases. These agents may cause severe adverse effects and among them liver failure, although rare, is a potential lethal one. This case illustrates the sudden and abrupt deterioration of hepatic function due to antithyroid drug administration. This case along with a concise literature review is presented aiming to increase the awareness of endocrinologists of possible fatal complications from the everyday use of common agents such as antithyroid drugs.

show abstract

“…17 Carbimazole-induced hepatotoxicity, mainly in the form of cholestasis, is reported in 14 cases in medical literature. 4,[17][18][19][20][21][22][23][24][25][26][27][28][29] These cases are summarized in Table 1. Three patients with additional risk factors for liver injury 30 -32 and 1 patient with undocumented hyperbilirubinemia 33 were excluded.…”

Section: Discussionmentioning

confidence: 99%